BioSpace News Archive

Neuronetics, Inc., a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the granting of inducement awards to five new non-executive employees.

Bio-Path Holdings, Inc. announced an upcoming poster presentation at the 2022 American Association for Cancer Research Annual Meeting, taking place in Atlanta, GA on April 8-13, 2022.

Checkmate Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, announced that it will present biomarker data at the 2022 American Association for Cancer Research Annual Meeting taking place in New Orleans, Louisiana from April 8-13, 2022.

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced three poster presentations and one oral presentation at the 2022 American Association for Cancer Research Annual Meeting taking place April 8-13, 2022, in New Orleans, LA.

Tempest Therapeutics, Inc., a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, announced two poster presentations at the 2022 American Association for Cancer Research virtual annual meeting taking place April 8-13, 2022.

Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will present four posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 8 to 13, 2022.

IO Biotech announced that an abstract from its MM1636 Phase 1/2 clinical trial evaluating IO102-IO103 in metastatic melanoma has been accepted for presentation as an e-poster at the American Association of Cancer Research conference, to be held April 8-13, 2022 in New Orleans, Louisiana.

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced it plans to release financial results from the fourth quarter and full year 2021 after the close of trading on March 15, 2022.

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), today announced plans to present two posters related to nonclinical data for OP-1250, a potent, oral complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from April 8-13, 2022.